<?xml version="1.0" encoding="UTF-8" ?>
			<?xml-stylesheet href="/rss/rss2html.xsl" type="text/xsl" media="screen"?>
			<rss version="2.0" xmlns:alacra="http://www.alacra.com" xmlns:sdc="http://www.alacra.com/sdc" xmlns:bir="http://www.alacra.com/bir" xmlns:ccbn="http://www.alacra.com/ccbn" ><channel><title>The Spectranetics Corporation RSS Research Feed - Subscribe Today - AlacraStore.com</title>
<description>The Spectranetics Corporation</description>
<link>http://www.alacrastore.com/company-snapshot/The_Spectranetics_Corporation-1057633</link>
<lastBuildDate>Monday, September 08, 2008 1:19:43 PM</lastBuildDate>
<alacra:xlsid>1057633</alacra:xlsid>
<alacra:company>The Spectranetics Corporation</alacra:company>
<language>en</language>
<generator>AlacraStore RSS Builder 1.0</generator>
<ttl>30</ttl>
<item><link>http://www.alacrastore.com/storecontent/ccbn/T1904575</link><guid isPermaLink="false">ccbn/T1904575</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to the Spectranetics Second Quarter Conference Call. (Operator Instructions) As a reminder, this conference is being recorded today, July ##, ####. I would now like to turn the conference call over to Mr. Markley. Please go ahead, sir. ...

</description><pubDate>7/29/2008 8:05:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics Q2 2008 Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">SPNC</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Spectranetics Q2 2008 Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1904575</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><title>Spectranetics Corp acquires Kensey Nash Corp-Endovascular from Kensey Nash Corp (pending)</title><description>US - Spectranetics Corp definitively agreed to acquire the endovascular business of Kensey Nash Corp, a manufacturer of biomaterials products, for $## mil. The consideration was to consist of $## mil in cash and up to $## mil in profit-related payments. The transaction was subject to customary closing conditions.</description><pubDate>5/14/2008 1:47:25 PM</pubDate><sdc:company_cusip xmlns:sdc="http://www.alacra.com/sdc">84760C</sdc:company_cusip><sdc:target_company_cusip xmlns:sdc="http://www.alacra.com/sdc">49005A</sdc:target_company_cusip><sdc:company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">84760C</sdc:company_cusip_up><sdc:target_company_cusip_up xmlns:sdc="http://www.alacra.com/sdc">490057</sdc:target_company_cusip_up><sdc:company xmlns:sdc="http://www.alacra.com/sdc">Spectranetics Corp</sdc:company><sdc:target_company xmlns:sdc="http://www.alacra.com/sdc">Kensey Nash Corp-Endovascular Business</sdc:target_company><sdc:company_up xmlns:sdc="http://www.alacra.com/sdc">Spectranetics Corp</sdc:company_up><sdc:target_company_up xmlns:sdc="http://www.alacra.com/sdc">Kensey Nash Corp</sdc:target_company_up><link>http://www.alacrastore.com/storecontent/Thomson_M%26A/Spectranetics_Corp_acquires_Kensey_Nash_Corp_Endovascular_from_Kensey_Nash_Corp-1977199020</link><guid isPermaLink="false">sdc/1977199020</guid><sdc:deal xmlns:sdc="http://www.alacra.com/sdc"><sdc:deal_no>1977199020</sdc:deal_no><sdc:_copyright><sdc:value>Copyright Â© 2008, Thomson Financial, All Rights Reserved</sdc:value></sdc:_copyright><sdc:a_EXCHANGE><sdc:value>Nasdaq</sdc:value></sdc:a_EXCHANGE><sdc:a_MAINDUSTRY><sdc:value>Measuring, Medical, Photo Equipment; Clocks</sdc:value></sdc:a_MAINDUSTRY><sdc:a_NATION><sdc:value>United States</sdc:value></sdc:a_NATION><sdc:a_SICDESC><sdc:value>Surgical and medical instruments and apparatus</sdc:value></sdc:a_SICDESC><sdc:a_SICPI><sdc:value>3841</sdc:value></sdc:a_SICPI><sdc:a_STATE><sdc:value>CO</sdc:value></sdc:a_STATE><sdc:a_STATELONG><sdc:value>Colorado</sdc:value></sdc:a_STATELONG><sdc:a_STATUS><sdc:value>Public</sdc:value></sdc:a_STATUS><sdc:a_TICKER><sdc:value>SPNC</sdc:value></sdc:a_TICKER><sdc:asic_SIC><sdc:value sdc:p="0">3841:Surgical and medical instruments and apparatus</sdc:value><sdc:value sdc:p="1">3842:Orthopedic, prosthetic, and surgical supplies</sdc:value></sdc:asic_SIC><sdc:aupsic_SIC><sdc:value sdc:p="0">3841:Surgical and medical instruments and apparatus</sdc:value><sdc:value sdc:p="1">3842:Orthopedic, prosthetic, and surgical supplies</sdc:value></sdc:aupsic_SIC><sdc:b_MAINDUSTRY><sdc:value>Drugs</sdc:value></sdc:b_MAINDUSTRY><sdc:b_NATION><sdc:value>United States</sdc:value></sdc:b_NATION><sdc:b_SICDESC><sdc:value>Biological products, except diagnostic substances</sdc:value></sdc:b_SICDESC><sdc:b_SICPI><sdc:value>2836</sdc:value></sdc:b_SICPI><sdc:b_STATE><sdc:value>PA</sdc:value></sdc:b_STATE><sdc:b_STATELONG><sdc:value>Pennsylvania</sdc:value></sdc:b_STATELONG><sdc:b_STATUS><sdc:value>Subsidiary</sdc:value></sdc:b_STATUS><sdc:c_ACIDGEN><sdc:value>171057002</sdc:value></sdc:c_ACIDGEN><sdc:c2up_BUSS><sdc:value>Mnfr,whl excimer lasers</sdc:value></sdc:c2up_BUSS><sdc:c3up_BUSS><sdc:value>Mnfr biomaterials prod</sdc:value></sdc:c3up_BUSS><sdc:co_DESCR><sdc:value sdc:p="0">Cash</sdc:value><sdc:value sdc:p="1">Earnout</sdc:value></sdc:co_DESCR><sdc:cs_DESCR><sdc:value>Assets</sdc:value></sdc:cs_DESCR><sdc:d_TCIDGEN><sdc:value>1010369001</sdc:value></sdc:d_TCIDGEN><sdc:date_lastupdate><sdc:value>May 14 2008</sdc:value></sdc:date_lastupdate><sdc:finbltm_BV><sdc:value>0.00000</sdc:value></sdc:finbltm_BV><sdc:finbltm_CASH><sdc:value>0.00000</sdc:value></sdc:finbltm_CASH><sdc:finbltm_CASHFLOW><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW><sdc:finbltm_CASHFLOW1><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW1><sdc:finbltm_CASHFLOW2><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW2><sdc:finbltm_CASHFLOW3><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW3><sdc:finbltm_CASHFLOW4><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW4><sdc:finbltm_CASHFLOW5><sdc:value>0.00000</sdc:value></sdc:finbltm_CASHFLOW5><sdc:finbltm_COMEQ><sdc:value>0.00000</sdc:value></sdc:finbltm_COMEQ><sdc:finbltm_DEBTRAT><sdc:value>0.00000</sdc:value></sdc:finbltm_DEBTRAT><sdc:finbltm_DSER2><sdc:value>0.00000</sdc:value></sdc:finbltm_DSER2><sdc:finbltm_EBIT><sdc:value>0.00000</sdc:value></sdc:finbltm_EBIT><sdc:finbltm_EPS><sdc:value>0.00000</sdc:value></sdc:finbltm_EPS><sdc:finbltm_NI><sdc:value>0.00000</sdc:value></sdc:finbltm_NI><sdc:finbltm_PTINC><sdc:value>0.00000</sdc:value></sdc:finbltm_PTINC><sdc:finbltm_SALES><sdc:value>0.00000</sdc:value></sdc:finbltm_SALES><sdc:finbltm_STDEBT><sdc:value>0.00000</sdc:value></sdc:finbltm_STDEBT><sdc:finbltm_TASS><sdc:value>0.00000</sdc:value></sdc:finbltm_TASS><sdc:fiscal_ADCR><sdc:value>0.00000</sdc:value></sdc:fiscal_ADCR><sdc:fiscal_AEPS><sdc:value>0.00000</sdc:value></sdc:fiscal_AEPS><sdc:fiscal_ANI><sdc:value>0.00000</sdc:value></sdc:fiscal_ANI><sdc:fiscal_APFDCR><sdc:value>0.00000</sdc:value></sdc:fiscal_APFDCR><sdc:fiscal_ASALES><sdc:value>0.00000</sdc:value></sdc:fiscal_ASALES><sdc:fiscal_ATASS><sdc:value>0.00000</sdc:value></sdc:fiscal_ATASS><sdc:fiscal_RATE><sdc:value>0.00000</sdc:value></sdc:fiscal_RATE><sdc:g_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value></sdc:g_SEQ><sdc:g_TEST><sdc:value sdc:p="0">Spectranetics Corp, located in</sdc:value><sdc:value sdc:p="1">Colorado Springs, Colorado,</sdc:value><sdc:value sdc:p="2">manufactures and wholesales</sdc:value><sdc:value sdc:p="3">excimer laser and laser</sdc:value><sdc:value sdc:p="4">ablation systems for use in</sdc:value><sdc:value sdc:p="5">multiple, minimally invasive</sdc:value><sdc:value sdc:p="6">cardiovascular procedures. The</sdc:value><sdc:value sdc:p="7">company was founded in 1984.</sdc:value></sdc:g_TEST><sdc:g_business><sdc:value sdc:p="0">Spectranetics Corp, located in Colorado Springs, Colorado,</sdc:value><sdc:value sdc:p="1">manufactures and wholesales excimer laser and laser ablation</sdc:value><sdc:value sdc:p="2">systems for use in multiple, minimally invasive</sdc:value><sdc:value sdc:p="3">cardiovascular procedures. The company was founded in 1984.</sdc:value></sdc:g_business><sdc:g_business1><sdc:value>Spectranetics Corp, located in Colorado Springs, Colorado, manufactures and wholesales excimer laser and laser ablation systems for use in multiple, minimally invasive cardiovascular procedures. The company was founded in 1984.</sdc:value></sdc:g_business1><sdc:h_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value></sdc:h_SEQ><sdc:h_TEST><sdc:value sdc:p="0">The endovascular business of</sdc:value><sdc:value sdc:p="1">Kensey Nash Corp, located in</sdc:value><sdc:value sdc:p="2">Pennsylvania, manufactures</sdc:value><sdc:value sdc:p="3">biomaterials products.</sdc:value></sdc:h_TEST><sdc:h_business><sdc:value sdc:p="0">The endovascular business of Kensey Nash Corp, located in</sdc:value><sdc:value sdc:p="1">Pennsylvania, manufactures biomaterials products.</sdc:value></sdc:h_business><sdc:h_business1><sdc:value>The endovascular business of Kensey Nash Corp, located in Pennsylvania, manufactures biomaterials products.</sdc:value></sdc:h_business1><sdc:i_AFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_AFEEPCT><sdc:i_AFEETOT><sdc:value>0.00000</sdc:value></sdc:i_AFEETOT><sdc:i_ATERMFEE><sdc:value>0.00000</sdc:value></sdc:i_ATERMFEE><sdc:i_COMOUT><sdc:value>0.00000</sdc:value></sdc:i_COMOUT><sdc:i_CROSS1><sdc:value>N</sdc:value></sdc:i_CROSS1><sdc:i_CURRENCYLONG><sdc:value>U.S. Dollar</sdc:value></sdc:i_CURRENCYLONG><sdc:i_DATEANN><sdc:value>13 May 08</sdc:value></sdc:i_DATEANN><sdc:i_DATEANN2><sdc:value>Tue, 13 May 2008 00:00:00 EST</sdc:value></sdc:i_DATEANN2><sdc:i_DATEANNS><sdc:value>Date Announced: 05/13/2008</sdc:value></sdc:i_DATEANNS><sdc:i_DATEEFFS><sdc:value>Date Effective:</sdc:value></sdc:i_DATEEFFS><sdc:i_DESCR><sdc:value>Acq. of Assets</sdc:value></sdc:i_DESCR><sdc:i_DESCR1><sdc:value>Friendly</sdc:value></sdc:i_DESCR1><sdc:i_FEEPCT><sdc:value>0.00000</sdc:value></sdc:i_FEEPCT><sdc:i_FEETOT><sdc:value>0.00000</sdc:value></sdc:i_FEETOT><sdc:i_HOSTAFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTAFEETOT><sdc:i_HOSTENTVAL><sdc:value>0.00000</sdc:value></sdc:i_HOSTENTVAL><sdc:i_HOSTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTFEETOT><sdc:i_HOSTPR><sdc:value>0.00000</sdc:value></sdc:i_HOSTPR><sdc:i_HOSTPRLABEL><sdc:value>Price/Share</sdc:value></sdc:i_HOSTPRLABEL><sdc:i_HOSTTFEETOT><sdc:value>0.00000</sdc:value></sdc:i_HOSTTFEETOT><sdc:i_HOSTVALUE><sdc:value>24 U.S. Dollar</sdc:value></sdc:i_HOSTVALUE><sdc:i_HOSTVALUE1><sdc:value>24.00000</sdc:value></sdc:i_HOSTVALUE1><sdc:i_HOST_EQVAL><sdc:value>0.00000</sdc:value></sdc:i_HOST_EQVAL><sdc:i_HOST_RANKVAL><sdc:value>24 U.S. Dollar</sdc:value></sdc:i_HOST_RANKVAL><sdc:i_HOST_RANKVAL1><sdc:value>24.00000</sdc:value></sdc:i_HOST_RANKVAL1><sdc:i_PCTACQ><sdc:value>0.00000</sdc:value></sdc:i_PCTACQ><sdc:i_PCTOWN><sdc:value>0.00000</sdc:value></sdc:i_PCTOWN><sdc:i_PR><sdc:value>0.00000</sdc:value></sdc:i_PR><sdc:i_PR_INITIAL><sdc:value>0.00000</sdc:value></sdc:i_PR_INITIAL><sdc:i_RANKVAL><sdc:value>24.00000</sdc:value></sdc:i_RANKVAL><sdc:i_RANK_HOSTRANKVAL><sdc:value>24 U.S. Dollar</sdc:value></sdc:i_RANK_HOSTRANKVAL><sdc:i_RATE><sdc:value>1.00000</sdc:value></sdc:i_RATE><sdc:i_STATUS_MMC><sdc:value>N</sdc:value></sdc:i_STATUS_MMC><sdc:i_STGVAL><sdc:value>12.33800</sdc:value></sdc:i_STGVAL><sdc:i_TERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TERMFEE><sdc:i_TFEEPCT><sdc:value>0.00000</sdc:value></sdc:i_TFEEPCT><sdc:i_TFEETOT><sdc:value>0.00000</sdc:value></sdc:i_TFEETOT><sdc:i_TTERMFEE><sdc:value>0.00000</sdc:value></sdc:i_TTERMFEE><sdc:i_VALLIA><sdc:value>0.00000</sdc:value></sdc:i_VALLIA><sdc:i_VALNOLIA><sdc:value>24.00000</sdc:value></sdc:i_VALNOLIA><sdc:i_VALUE><sdc:value>24.00000</sdc:value></sdc:i_VALUE><sdc:j_EQVALCF><sdc:value>0.00000</sdc:value></sdc:j_EQVALCF><sdc:j_EVCF><sdc:value>0.00000</sdc:value></sdc:j_EVCF><sdc:j_EVEBIT><sdc:value>0.00000</sdc:value></sdc:j_EVEBIT><sdc:j_EVNI><sdc:value>0.00000</sdc:value></sdc:j_EVNI><sdc:j_EVSALES><sdc:value>0.00000</sdc:value></sdc:j_EVSALES><sdc:j_MPRICEBOOK><sdc:value>0.00000</sdc:value></sdc:j_MPRICEBOOK><sdc:j_PHELD><sdc:value>0.00000</sdc:value></sdc:j_PHELD><sdc:j_PSOUGHT><sdc:value>100.00000</sdc:value></sdc:j_PSOUGHT><sdc:j_RANKVALCF><sdc:value>0.00000</sdc:value></sdc:j_RANKVALCF><sdc:j_RANKVALEB><sdc:value>0.00000</sdc:value></sdc:j_RANKVALEB><sdc:j_RANKVALNA><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNA><sdc:j_RANKVALNI><sdc:value>0.00000</sdc:value></sdc:j_RANKVALNI><sdc:j_RANKVALSALES><sdc:value>0.00000</sdc:value></sdc:j_RANKVALSALES><sdc:j_VALEB><sdc:value>0.00000</sdc:value></sdc:j_VALEB><sdc:j_VALNI><sdc:value>0.00000</sdc:value></sdc:j_VALNI><sdc:j_VALSALES><sdc:value>0.00000</sdc:value></sdc:j_VALSALES><sdc:m_AMV><sdc:value>0.00000</sdc:value></sdc:m_AMV><sdc:m_CF3YGR><sdc:value>0.00000</sdc:value></sdc:m_CF3YGR><sdc:m_CF5YGR><sdc:value>0.00000</sdc:value></sdc:m_CF5YGR><sdc:m_DCR><sdc:value>0.00000</sdc:value></sdc:m_DCR><sdc:m_ENTVAL><sdc:value>0.00000</sdc:value></sdc:m_ENTVAL><sdc:m_EPS3YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS3YGR><sdc:m_EPS5YGR><sdc:value>0.00000</sdc:value></sdc:m_EPS5YGR><sdc:m_LTD><sdc:value>0.00000</sdc:value></sdc:m_LTD><sdc:m_MV><sdc:value>0.00000</sdc:value></sdc:m_MV><sdc:m_NETASS><sdc:value>0.00000</sdc:value></sdc:m_NETASS><sdc:m_NETASS3YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS3YGR><sdc:m_NETASS5YGR><sdc:value>0.00000</sdc:value></sdc:m_NETASS5YGR><sdc:m_NI3YGR><sdc:value>0.00000</sdc:value></sdc:m_NI3YGR><sdc:m_NI5YGR><sdc:value>0.00000</sdc:value></sdc:m_NI5YGR><sdc:n_SEQ><sdc:value sdc:p="0">1.00000</sdc:value><sdc:value sdc:p="1">2.00000</sdc:value><sdc:value sdc:p="2">3.00000</sdc:value><sdc:value sdc:p="3">4.00000</sdc:value><sdc:value sdc:p="4">5.00000</sdc:value><sdc:value sdc:p="5">6.00000</sdc:value><sdc:value sdc:p="6">7.00000</sdc:value><sdc:value sdc:p="7">8.00000</sdc:value><sdc:value sdc:p="8">9.00000</sdc:value><sdc:value sdc:p="9">10.00000</sdc:value><sdc:value sdc:p="10">11.00000</sdc:value><sdc:value sdc:p="11">12.00000</sdc:value></sdc:n_SEQ><sdc:n_SYNOPSIS><sdc:value sdc:p="0">US - Spectranetics Corp</sdc:value><sdc:value sdc:p="1">definitively agreed to acquire</sdc:value><sdc:value sdc:p="2">the endovascular business of</sdc:value><sdc:value sdc:p="3">Kensey Nash Corp, a</sdc:value><sdc:value sdc:p="4">manufacturer of biomaterials</sdc:value><sdc:value sdc:p="5">products, for $24 mil. The</sdc:value><sdc:value sdc:p="6">consideration was to consist</sdc:value><sdc:value sdc:p="7">of $10 mil in cash and up to</sdc:value><sdc:value sdc:p="8">$14 mil in profit-related</sdc:value><sdc:value sdc:p="9">payments. The transaction was</sdc:value><sdc:value sdc:p="10">subject to customary closing</sdc:value><sdc:value sdc:p="11">conditions.</sdc:value></sdc:n_SYNOPSIS><sdc:n_synopsis2><sdc:value>US - Spectranetics Corp definitively agreed to acquire the endovascular business of Kensey Nash Corp, a manufacturer of biomaterials products, for $24 mil. The consideration was to consist of $10 mil in cash and up to $14 mil in profit-related payments. The transaction was subject to customary closing conditions.</sdc:value></sdc:n_synopsis2><sdc:n_synopsis3><sdc:value sdc:p="0">US - Spectranetics Corp definitively agreed to acquire the endovascular business of Kensey</sdc:value><sdc:value sdc:p="1">Nash Corp, a manufacturer of biomaterials products, for $24 mil. The consideration was to</sdc:value><sdc:value sdc:p="2">consist of $10 mil in cash and up to $14 mil in profit-related payments. The transaction</sdc:value><sdc:value sdc:p="3">was subject to customary closing conditions.</sdc:value></sdc:n_synopsis3><sdc:n_synopsis4><sdc:value sdc:p="0">US - Spectranetics Corp definitively agreed to acquire the endovascular business of Kensey Nash Corp, a manufacturer of biomaterials products, for $24 mil. The consideration was to consist of $10 mil</sdc:value><sdc:value sdc:p="1">in cash and up to $14 mil in profit-related payments. The transaction was subject to customary closing conditions.</sdc:value></sdc:n_synopsis4><sdc:n_synopsis5><sdc:value sdc:p="0">US - Spectranetics Corp definitively agreed to acquire the endovascular business of Kensey Nash Corp, a manufacturer of biomaterials</sdc:value><sdc:value sdc:p="1">products, for $24 mil. The consideration was to consist of $10 mil in cash and up to $14 mil in profit-related payments. The transaction</sdc:value><sdc:value sdc:p="2">was subject to customary closing conditions.</sdc:value></sdc:n_synopsis5><sdc:q_DESCR><sdc:value>Pending</sdc:value></sdc:q_DESCR><sdc:q_HOSTANETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTANETASS><sdc:q_HOSTANILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTANILTM><sdc:q_HOSTASALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTASALESLTM><sdc:q_HOSTATASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTATASS><sdc:q_HOSTBOOKVALUE><sdc:value>0.00000</sdc:value></sdc:q_HOSTBOOKVALUE><sdc:q_HOSTCASHFLOW><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW><sdc:q_HOSTCASHFLOW1><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW1><sdc:q_HOSTCASHFLOW2><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW2><sdc:q_HOSTCASHFLOW3><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW3><sdc:q_HOSTCASHFLOW4><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW4><sdc:q_HOSTCASHFLOW5><sdc:value>0.00000</sdc:value></sdc:q_HOSTCASHFLOW5><sdc:q_HOSTCOMMONEQUITY><sdc:value>0.00000</sdc:value></sdc:q_HOSTCOMMONEQUITY><sdc:q_HOSTEBITLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEBITLTM><sdc:q_HOSTEPS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS1><sdc:q_HOSTEPS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS2><sdc:q_HOSTEPS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS3><sdc:q_HOSTEPS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS4><sdc:q_HOSTEPS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPS5><sdc:q_HOSTEPSLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTEPSLTM><sdc:q_HOSTNETASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS><sdc:q_HOSTNETASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS1><sdc:q_HOSTNETASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS2><sdc:q_HOSTNETASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS3><sdc:q_HOSTNETASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS4><sdc:q_HOSTNETASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNETASS5><sdc:q_HOSTNI1><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI1><sdc:q_HOSTNI2><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI2><sdc:q_HOSTNI3><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI3><sdc:q_HOSTNI4><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI4><sdc:q_HOSTNI5><sdc:value>0.00000</sdc:value></sdc:q_HOSTNI5><sdc:q_HOSTNILTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTNILTM><sdc:q_HOSTPTINC1><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC1><sdc:q_HOSTPTINC2><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC2><sdc:q_HOSTPTINC3><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC3><sdc:q_HOSTPTINC4><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC4><sdc:q_HOSTPTINC5><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINC5><sdc:q_HOSTPTINCLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTPTINCLTM><sdc:q_HOSTSALES1><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES1><sdc:q_HOSTSALES2><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES2><sdc:q_HOSTSALES3><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES3><sdc:q_HOSTSALES4><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES4><sdc:q_HOSTSALES5><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALES5><sdc:q_HOSTSALESLTM><sdc:value>0.00000</sdc:value></sdc:q_HOSTSALESLTM><sdc:q_HOSTTASS><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS><sdc:q_HOSTTASS1><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS1><sdc:q_HOSTTASS2><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS2><sdc:q_HOSTTASS3><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS3><sdc:q_HOSTTASS4><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS4><sdc:q_HOSTTASS5><sdc:value>0.00000</sdc:value></sdc:q_HOSTTASS5><sdc:q_STATUS><sdc:value>Status:Pending</sdc:value></sdc:q_STATUS><sdc:r_PE><sdc:value>-999.00000</sdc:value></sdc:r_PE><sdc:r_PE_PRINT><sdc:value>np</sdc:value></sdc:r_PE_PRINT><sdc:r_PFTMARG><sdc:value>0.00000</sdc:value></sdc:r_PFTMARG><sdc:r_PRICEBOOK><sdc:value>-999.00000</sdc:value></sdc:r_PRICEBOOK><sdc:r_PRICEBOOK_PRINT><sdc:value>np</sdc:value></sdc:r_PRICEBOOK_PRINT><sdc:r_PTINC3YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC3YGR><sdc:r_PTINC5YGR><sdc:value>0.00000</sdc:value></sdc:r_PTINC5YGR><sdc:r_ROE><sdc:value>0.00000</sdc:value></sdc:r_ROE><sdc:r_SALES3YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES3YGR><sdc:r_SALES5YGR><sdc:value>0.00000</sdc:value></sdc:r_SALES5YGR><sdc:r_SE><sdc:value>0.00000</sdc:value></sdc:r_SE><sdc:r_TASS3YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS3YGR><sdc:r_TASS5YGR><sdc:value>0.00000</sdc:value></sdc:r_TASS5YGR><sdc:r_TTCFMULT><sdc:value>0.00000</sdc:value></sdc:r_TTCFMULT><sdc:r_TTEBITMULT><sdc:value>0.00000</sdc:value></sdc:r_TTEBITMULT><sdc:r_VALNA><sdc:value>0.00000</sdc:value></sdc:r_VALNA><sdc:sic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value><sdc:value sdc:p="3">3841:Surgical and medical instruments and apparatus</sdc:value><sdc:value sdc:p="4">8731:Commercial physical and biological research</sdc:value></sdc:sic_SIC><sdc:upa_UPACIDGEN><sdc:value>171057002</sdc:value></sdc:upa_UPACIDGEN><sdc:upa1_EXCHANGE><sdc:value>Nasdaq</sdc:value></sdc:upa1_EXCHANGE><sdc:upa1_NATION><sdc:value>United States</sdc:value></sdc:upa1_NATION><sdc:upa1_SICP><sdc:value>3841</sdc:value></sdc:upa1_SICP><sdc:upa1_STATE><sdc:value>Colorado</sdc:value></sdc:upa1_STATE><sdc:upa1_STATUS><sdc:value>Public</sdc:value></sdc:upa1_STATUS><sdc:upa1_TICKER><sdc:value>SPNC</sdc:value></sdc:upa1_TICKER><sdc:upsic_SIC><sdc:value sdc:p="0">2833:Medicinal chemicals and botanical products</sdc:value><sdc:value sdc:p="1">2834:Pharmaceutical preparations</sdc:value><sdc:value sdc:p="2">2836:Biological products, except diagnostic substances</sdc:value><sdc:value sdc:p="3">3841:Surgical and medical instruments and apparatus</sdc:value><sdc:value sdc:p="4">8731:Commercial physical and biological research</sdc:value></sdc:upsic_SIC><sdc:upt_UPTCIDGEN><sdc:value>149669002</sdc:value></sdc:upt_UPTCIDGEN><sdc:upt1_EXCHANGE><sdc:value>Nasdaq</sdc:value></sdc:upt1_EXCHANGE><sdc:upt1_NATION><sdc:value>United States</sdc:value></sdc:upt1_NATION><sdc:upt1_SICP><sdc:value>2836</sdc:value></sdc:upt1_SICP><sdc:upt1_STATE><sdc:value>Pennsylvania</sdc:value></sdc:upt1_STATE><sdc:upt1_STATUS><sdc:value>Public</sdc:value></sdc:upt1_STATUS><sdc:upt1_TICKER><sdc:value>KNSY</sdc:value></sdc:upt1_TICKER><sdc:x_RANK1_VALUE><sdc:value>24.00000</sdc:value></sdc:x_RANK1_VALUE><sdc:x_RANK_HOSTRANKVAL><sdc:value>24.00000</sdc:value></sdc:x_RANK_HOSTRANKVAL><sdc:x_RANK_RANKVAL><sdc:value>24.00000</sdc:value></sdc:x_RANK_RANKVAL><sdc:x_rank_rankstgval><sdc:value>12.33800</sdc:value></sdc:x_rank_rankstgval></sdc:deal><category>Deal Information</category><alacra:ip>Thomson Financial Mergers &amp; Acquisitions</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1850704</link><guid isPermaLink="false">ccbn/T1850704</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to the Spectranetics Corporation business update conference call. Following management's prepared remarks, we'll hold a Q&amp;A session. (OPERATOR INSTRUCTIONS). As a reminder, this conference is being recorded today, May ##, ####. I would now like to turn the conference over to Don Markley. Please go ahead, sir. ...

</description><pubDate>5/13/2008 5:06:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics Acquires Endovascular Business of Kensey Nash Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">SPNC</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">1:30pm ET</ccbn:time><title>Spectranetics Acquires Endovascular Business of Kensey Nash Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1850704</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1825304</link><guid isPermaLink="false">ccbn/T1825304</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Welcome to the Spectranetics #### First Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode. Following management's prepared remarks, we'll hold a Q&amp;A session. To ask a question please press * followed by # on your touchtone phone. If anyone has difficulty hearing the conference please press *# for Operator assistance. As a reminder, this conference is being recorded today, April ##, ####. I would now like to turn the conference over to Mr. Don Markley. Sir, you may begin your conference. ...

</description><pubDate>4/23/2008 7:04:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q1 2008 Spectranetics Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">SPNC</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">10:00am ET</ccbn:time><title>Q1 2008 Spectranetics Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1825304</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/bir/267808</link><guid isPermaLink="false">bir/267808</guid><bir:index_mode xmlns:bir="http://www.alacra.com/bir">norm</bir:index_mode><title>Spectranetics Corp.</title><bir:company xmlns:bir="http://www.alacra.com/bir">Spectranetics Corp.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">Advanced Interventional Systems Inc.</bir:company><bir:company xmlns:bir="http://www.alacra.com/bir">The Spectranetics Corp.</bir:company><bir:cou xmlns:bir="http://www.alacra.com/bir">United States</bir:cou><bir:descr xmlns:bir="http://www.alacra.com/bir">Manufacturing: Manufactures and develops laser systems and catheters used for heart angioplasty surgery. Wholesale: Surgical and other medical instruments, apparatus, and equipment.</bir:descr><bir:sic xmlns:bir="http://www.alacra.com/bir">3845</bir:sic><bir:ssic xmlns:bir="http://www.alacra.com/bir">3841</bir:ssic><bir:ssic xmlns:bir="http://www.alacra.com/bir">5047</bir:ssic><bir:naics xmlns:bir="http://www.alacra.com/bir">334510</bir:naics><bir:snaics xmlns:bir="http://www.alacra.com/bir">339112</bir:snaics><bir:snaics xmlns:bir="http://www.alacra.com/bir">423450</bir:snaics><bir:class xmlns:bir="http://www.alacra.com/bir">2</bir:class><bir:class xmlns:bir="http://www.alacra.com/bir">17</bir:class><bir:size xmlns:bir="http://www.alacra.com/bir">D</bir:size><bir:revenue xmlns:bir="http://www.alacra.com/bir">G</bir:revenue><bir:ticker xmlns:bir="http://www.alacra.com/bir">SPNC</bir:ticker><pubDate>3/26/2008 6:18:00 AM</pubDate><bir:docid xmlns:bir="http://www.alacra.com/bir">267808</bir:docid><category>Company Profiles &amp; Financials</category><alacra:ip>Gale Company Profiles</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1761097</link><guid isPermaLink="false">ccbn/T1761097</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><description>...Good morning, and welcome to The Spectranetics #### fourth-quarter financial result conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we'll hold a Q&amp;A session. (OPERATOR INSTRUCTIONS) As a reminder, this conference is being recorded February ##th, ####. I would now like to turn the conference over to Don Markley. Please go ahead, sir. ...

</description><pubDate>2/20/2008 1:06:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q4 2007 Spectranetics Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">SPNC</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q4 2007 Spectranetics Earnings Conference Call Transcript</title><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1761097</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item><item><link>http://www.alacrastore.com/storecontent/ccbn/T1673226</link><guid isPermaLink="false">ccbn/T1673226</guid><ccbn:index_mode xmlns:ccbn="http://www.alacra.com/ccbn">norm</ccbn:index_mode><pubDate>10/31/2007 6:06:00 PM</pubDate><ccbn:name xmlns:ccbn="http://www.alacra.com/ccbn">Spectranetics</ccbn:name><ccbn:price xmlns:ccbn="http://www.alacra.com/ccbn">54.0000</ccbn:price><ccbn:revision xmlns:ccbn="http://www.alacra.com/ccbn">Final</ccbn:revision><ccbn:storetitle xmlns:ccbn="http://www.alacra.com/ccbn">Q3 2007 Spectranetics Earnings Conference Call Transcript</ccbn:storetitle><ccbn:ticker xmlns:ccbn="http://www.alacra.com/ccbn">SPNC</ccbn:ticker><ccbn:time xmlns:ccbn="http://www.alacra.com/ccbn">11:00am ET</ccbn:time><title>Q3 2007 Spectranetics Earnings Conference Call Transcript</title><description>...Welcome to the Spectranetics #### Third Quarter Financial Results Conference Call. At this time all participants are in a listen-only mode. Following management's prepared remarks, we'll hold a Q&amp;A session. To ask a question please press * followed by # on your touchtone phone. If anyone has difficulty hearing the conference please press *# for Operator assistance. As a reminder, this conference is being recorded today, October ##, ####. I'd now like to turn the conference over to Mr. Don Markley. Please go ahead sir. ...

</description><ccbn:type xmlns:ccbn="http://www.alacra.com/ccbn">Transcript</ccbn:type><ccbn:docid xmlns:ccbn="http://www.alacra.com/ccbn">T1673226</ccbn:docid><category>Credit &amp; Investment Research</category><alacra:ip>Thomson Street Events</alacra:ip></item></channel></rss>